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Biological, especially biotechnology-derived medicinal prod-
ucts, have enjoyed very high success during recent years. Sev-
eral rare diseases have, for the first time, been managed with
effective therapies, and significant progress has been made in
the treatment of many common diseases. The development
of gene and cell therapies and tissue engineering products
has reached the stage where therapeutic breakthroughs are to
be expected in the next few years.
The development and introduction into use of therapies
based on new mechanisms of action and technologies are
always associated with uncertainties. The drug regulatory
authorities are continuously struggling to find a balance
between the application of the most recent achievements in
science and technology and ensuring the safety of patients.
Excessive boldness may eventually cause safety problems, but
then again excessive cautiousness and an urge towards self-
protection will slow down development and delay the intro-
duction of new therapies.
The European Medicines Agency (EMEA) and its Com-
mittee for Medical Products for Human Use (CHMP) are in
the forefront of regulation of the recent biotechnology-
derived medicinal products. The authorities are making an
effort to keep up with ongoing developments in science and
technology. The experts of EMEA and CHMP, in collabora-
tion with the pharmaceutical companies and scientific
organisations, are at present examining ways to facilitate the
introduction of new innovative medicinal products on to the
market (Innovation and Drug Development in Europe,
“Innovation Think Tank”). As set out by its strategy, NAM
has been active in this and other development programmes
focusing on the development and regulation of biological
medicinal products. The experts of NAM have become res-
olutely engaged in solving current topics in their area, such
as similar biological medicinal products, nanoparticles acti-
vated in the cells, and the use of autologous cells for various
therapeutic purposes.
These complicated issues typically relate to new spheres
of science and technology of which the drug regulatory
authorities have no previous experience, or to areas which
fall in between the different regulatory sectors (e.g. combina-
tions of medicines and medical devices). In those sectors of
influence within the EU in which it has chosen to be a part,
NAM relies heavily on its national networks of experts. The
assignments of expertise within NAM provide an opportuni-
ty for university and hospital experts to familiarise
themselves with the technical and clinical applications of
top-level research before they become public. For NAM, this
opens up an opportunity to get a balanced overall view of
the complicated and novel innovations.
Drug development is able to be tracked down easily from
its very first stages up to the evaluation of the application for
marketing authorisation. The risk management of new ther-
apies can be developed by making use of and combining var-
ious health care registers. In Finland, for example, it is possi-
ble to carry out extensive epidemiological studies into the
effects of modern vaccines. Well organised post-marketing
safety surveillance benefit both the patients and the drug
developers, allowing safe introduction into use of new
biotechnological medicinal products.
The pharmaceutical industry which develops biological
medicinal products is in the forefront of innovations along
the route staked out by primary research. The risks, both
financial and those relating to drug safety, are high. Success-
ful outcomes naturally lead to success stories about medical
therapies and hence to continued investments in research by
drug companies. NAM offers the companies the best possi-
ble scientific and administrative advice in support of the suc-
cess stories, without haggling over safety.
The development of biological medicinal products:
innovations and regulation
Drug treatment has an aim the dis-
pense the correct drug in the correct
dose to the correct patient via the cor-
rect route of administration and at the
correct time. 
The viewpoint traditionally taken
in health care is that errors will not
occur and must not occur. The confi-
dence in the health care staff ’s faultless
operation has been high. Nevertheless,
the fact that there are deficiencies in
the safety and quality of health care is
gradually coming to be understood.
In the United States discussion
about patient safety was triggered by a
report by the Institute of Medicine
(IOM), ‘To err is human’ (IOM
2000). According to the report, an
estimate of 44,000–98,000 patients die
and over a million suffer injuries every
year as a result of a treatment error. Of
these deaths, 7,000 have been associat-
ed with medication errors. Finland has
participated in the work of experts in
the Council of Europe with the aim of
formulating recommendations in order
to improve the safety of patients and
their medication.
A medication error is defined as an
event associated with a drug therapy
which can lead to a risk and which
may be caused by something that has
been done, or been ignored, or by safe-
ty measures that failed. A medical error
can occur at any stage of the drug
therapy and treatment, and at anytime
between the prescribing and dispensing
and the administration and follow-up
(National Coordinating Council of
Medicat-ion Errors and Prevention,
NCC MERP 1998). A dispensing
error is considered to have occurred
when the strength, dosage, pharmaceu-
tical form or a dosage of a medicinal
product dispensed by a pharmacy dif-
fers from that prescribed by the doctor.
A dispensing error has also occurred if
the drug dispensed is outdated,
supplied with inadequate or incorrect
instructions and labelling, or if the
drug is manufactured, packed or stored
incorrectly before dispensing from the
pharmacy.
The survey was carried out by
sending a questionnaire to all private
main pharmacies in Finland (n=599)
in March 2005. The questionnaire was
completed by over a half (n=340) of
private main pharmacies in Finland
(response percentage 57%).
Prevalence of dispensing
errors
The pharmacies were requested to state
the number and type or evaluation of
any dispensing errors recorded in 2004
(Savikko 2006). Of those completing
the questionnaire, 66% reported the
dispensing errors recorded and 31%
gave their evaluation of them. The
pharmacies had recorded a total of
1,955 dispensing errors, (8.7 errors per
pharmacy) during 2004. The estimated
numbers of dispensing errors were also
close to the published numbers, an
average estimate of 8.4 errors per phar-
macy. The frequency of errors from
prescriptions was one per 6,000
prescriptions. According to the phar-
macies, not all errors are recorded and
some pharmacies do not record them
at all. The most common dispensing
errors consisted of incorrect strengths,
packet sizes and pharmaceutical forms.
Causes and prevention of 
dispensing errors
Dispensing errors are caused by factors
associated with the working environ-
ment, the nature and actions of phar-
macists, the prescriptions, the drugs
and the patients. The most common
individual causes were considered to be
shortage of time, ambiguous or inaccu-
rate prescriptions, carelessness on the
part of the pharmacist, and similarities
between packages. Ambiguous and
inaccurate prescriptions were the result
of obscure handwriting, obscure notes
including e.g. abbreviations and
renewals, and inaccurate notes, for
instance regarding computerised pre-
scriptions or therapeutic indications.
The survey participants considered
that the dispensing errors from
prescriptions could mostly be prevent-
ed by carefulness, concentration, accu-
racy and attentiveness on the part of
the staff at all stages of the process,
calm and undisturbed working
environment, wider introduction of
computerised prescriptions, adequate
numbers of staff, and discussing the
dispensing errors that have occurred
with the staff.
Handling of dispensing errors
The majority of the survey participants
(59%) had written instructions for the
handling of dispensing errors. Most of
the participants (89%) said their phar-
macy would always reimburse the
client for any error, and the rest (11%)
also said they would nearly always do
so. Dispensing errors are always or
nearly always recorded by 76% of the
pharmacies in the survey. The record-
ing was almost as often made anony-
mously. Dispensing error cases are
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To err is human
A survey of dispensing errors made by pharmacies in Finland
more often discussed with the individ-
ual involved rather than jointly with
the staff.
Most of the survey participants
emphasised the importance of record-
ing the errors and discussing the case
jointly with the staff. According to the
survey participants, this would make it
easier to follow the possible causes of
the errors and to discuss openly ways
to reduce errors. Suggested ways of
handling the errors included principal-
ly a rectification of the error and reim-
bursing the customer, as well as writ-
ten instructions for handling of the
dispensing errors.
Conclusion
Pharmacies make an effort to take a
systematic approach to the handling of
dispensing errors. This is seen, for
example, in the written instructions
available in pharmacies and in the
reporting practices adopted for errors.
In a large number of pharmacies any
errors that have occurred are recorded
and are discussed later jointly by the
staff. The frequency and common
practice of recording errors could nev-
ertheless be improved to achieve a
more complete picture of the errors
and near misses that have occurred.
The weakness of self-reporting is, in
fact, under-reporting of dispensing
errors (Ashcroft et al. 2006). A prereq-
uisite for reporting errors is being able
to detect them, and prevention
requires identification and recognition
of the errors. Reporting is made easier
by an open working community with a
tendency to discuss rather than
victimise. Self-reporting has been seen
to be a cost-effective method for fol-
lowing up dispensing errors, and the
only method suitable for continuous
use (Chua et al. 2003).
Previous surveys have indicated
pharmaceutical advice as playing a part
in the detection and prevention of
errors in dispensing (Abood 1996). As
a last resort, pharmaceutical advice
ensures that the correct drug is
dispensed to the correct customer.
According to one survey, as many as
83% of dispensing errors can be
detected and adjusted as a result of
pharmaceutical advice before the
wrong medicine reaches the customer
(Ukens 1997).
Pharmacies are also carefully
preparing themselves to use a national
reporting system of dispensing errors.
Reporting systems are in use in, for
example, the USA, UK and Denmark. 
The experience of pharmacists is
that the dispensing errors are mostly
due to the nature of the individual
rather than the operation of the entire
working community. Emphasis among
the causes and preventive factors for
the errors was laid on the individual’s
character, such as carefulness and abili-
ty to concentrate. There are two differ-
ent approaches that can be taken to
errors committed by humans; one of
them concentrates on the individual
and the other on the system (Reason
2000). The approach concentrating on
the system emphasises the organisation
and the circumstances in which the
individual works (DH 2000). This
approach takes into account the fact
that humans make mistakes and errors
are possible. They are seen as results
rather than causes, while their origin
lies in the system rather than in the
individual.
The collaboration between
pharmacies and prescribers could be
further improved. Pharmacies should
avoid excessive interpretation of
prescriptions in ambiguous cases and
contact the doctor to check prescrip-
tions and to ensure patient safety.
The customer was also considered
to play an error-promoting role, with a
hurried or unusual behaviour and a
large number of prescriptions. Creat-
ing undisturbed and calm conditions
for mechanical checking of drug dis-
pensing was seen as a solution.
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The Poison Information Centre
receives 40,000 telephone inquiries
every year, 30,000 of which concern
acute poisoning in humans. An average
of 200 of these telephone inquiries
relate to medication errors that have
occurred in health care.
A survey was carried out of the
telephone inquiries received by the
Poison Information Centre between
June 2000 and December 2005 in
which the cause was either a medica-
tion error or a suspected medication
error in humans. The use of an incor-
rect drug, dose or route of administra-
tion by a health care professional was
considered a medication error. 
Findings 
There were a total of 150,036 inquiries
about acute poisoning during the sur-
vey period, 852 (0.6 %) of which were
about medication errors. Fifty percent
of those in whom medication error
had occurred were women and 37%
were men. The sex was not reported in
12% of the cases and 1% of the
inquiries concerned more than one
patient. There were three main types of
errors (Figure).
The majority of the medication
errors reported occurred in the medica-
tion of children under 10 years of age
and the elderly between 80 and 89
years of age. The youngest patient was
one day old and the oldest 99 years of
age. The majority of calls were from
the Province of Southern Finland
(56%). The location where the medi-
cation error had taken place was usual-
ly registered when the call was made
from a health care unit. It was never-
theless not known in many cases,
because the patient had already been
moved to a health centre or hospital,
and contact was made from there.
The medication error was usually
detected quickly, and calls to the Poi-
son Information Centre regarding
severity and necessary measures were
made rather soon after the incident. A
total of 562 (66%) of the inquiries
were received within less than one
hour from the incident. Incorrect
doses were repeatedly administered to
61 patients (7%). Every year the num-
ber of inquiries has peaked in the sum-
mer months and in December, when
the number of permanent staff is lower
and the number of temporary replace-
ments higher than usual.
Incorrect drug
A total of 507 calls concerned the
administration of an incorrect medica-
tion, where it was usually a question of
administering a drug to the wrong
patient. 
The majority of cases of an incor-
rect drug having been administered
occurred in nursing homes or responsi-
ble care units for the elderly, for the
mentally retarded and for dementia
patients. The largest age group was the
80- to 89-year-olds, who made up
19% (94 patients) of the total.
The majority of the inquiries were
about drugs with a central nervous sys-
tem effect (61%), drugs with an effect
on the cardiovascular system (15%),
and drugs with an effect on the
alimentary tract and the metabolism
(6%). The most common medicinal
substances concerned included carba-
mazepine, sodium valproate, clozapine,
risperidone and lorazepam. Sixty-seven
percent of the calls concerned medica-
tion errors involving 1–3 drugs at the
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In English
same time; in 33% of the cases the
number of drugs erroneously used was
between 4 and 13. 
Incorrect dose
Enquiries were made in 299 calls
about the administration of an incor-
rect dose or a dose with an incorrect
strength. The majority of these also
occurred in nursing homes or responsi-
ble care units for the elderly, for the
mentally retarded and for dementia
patients. 
The incorrect dosages administered
were mostly to patients under 10 years
of age (24%), usually in hospital, at
the pharmacy, or in association with
vaccination. There were 8 newborns,
all of whom were incorrectly dosed in
hospital. Five of these infants had
received an overdose which was 10
times the required dose.
The groups of therapy most
frequently enquired about included
drugs with a CNS effect (71%),
systemic anti-infectives (19%), and
cardiovascular drugs (17%). The most
common drugs included vaccines,
sodium valproate, carbamazepine,
paracetamol and lamotrigine. Almost
80% of the inquiries concerned incor-
rect dosage of one medicinal substance. 
Incorrect route of 
administration
Forty-nine of the calls concerned cases
where an incorrect route of administra-
tion had been used. The calls were
usually made from hospitals, with the
majority of them concerning adults.
The largest age groups were the 80- to
89-year-olds (11 calls out of 49) and
under 10-year-olds (8 calls out of 49).
The groups of drugs about which
queries were most frequently raised
included systemic anti-infectives
(30%), drugs with a CNS effect (22%)
and drugs used to treat respiratory dis-
eases (8%). In most cases the drug had
been inadvertently administered via
the intravascular (38%), oral (10%) or
intramuscular route (8%). The most
common incorrect routes of adminis-
tration included the intravascular
administration of drugs intended for
intramuscular or oral administration. 
Inquiries concerning 
pharmacies
Seventeen (2%) of the 852 calls in
total were cases where a prescription
error was suspected of having occurred
in the pharmacy. The ages of the
patients varied between 6 months and
90 years: the under 16-year-olds num-
bered 11, the 16- to 75-year-olds 3,
and the over 75-year-olds 2 (in one
case, the age was unknown). Calls were
received from the public (10), the
pharmacy (6) and the physician (1).
The patient instructions supplied
with the drugs included 7 cases of
incorrect dosage instructions, and an
incorrect strength of the drug was sup-
plied by the pharmacy on 10 occa-
sions. In one case medicine was dis-
pensed incorrectly in the drug dis-
penser, and in the other case both
incorrect strength and dosage instruc-
tions were supplied. The majority of
inquiries made were about antimicro-
bials, cough medicine and antihista-
mines. 
Even though errors of this type can
in the worst scenario have severe con-
sequences, the medicines about which
queries were made were nevertheless in
a large number of cases fairly risk-free.
The Poison Information Centre
recommended follow-up at home for
15 patients, and two patients were
considered to need treatment by a
physician.
Symptoms and treatment
Of the total of 852 patients in the sur-
vey 77% were symptom-free at the
time of the call, probably owing to the
fact that the call was made not long
after the erroneous administration and
before any symptoms had developed.
No information is available about the
symptoms the patients possibly mani-
fested later and the treatment they may
have required. The longer the time
that had passed since the incident, the
higher the number of inquiries
concerning patients with symptoms.
About 75% of the patients could
remain in follow-up treatment at
home, and 25% were recommended
for treatment at a health centre or hos-
pitalisation.
Conclusions
The statistics of the Poison Inform-
ation Centre include telephone inquir-
ies spontaneously received about cases
of medication error or poisoning. 
The majority of inquiries received
by the Centre concerning erroneous
medication relate to a normal dose of
medicine being given to the wrong
patient. The error usually occurs in a
nursing home for the elderly to a
patient with several primary diseases
and on several drug therapies. Even if
it is a drug dose intended for a patient,
it may in another patient cause unex-
pectedly strong symptoms and even be
fatal.
When an accident occurs it is
important to act immediately and
establish whether the situation requires
any treatment measures. Information
about risks involved with medicines
and their dispensing should also be
increased, especially among staff work-
ing in in-patient wards, nursing homes
or responsible units.
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My patient is a 54-year-old office
worker, with asthma as her primary
disease since 1987. For the treatment
of her asthma the patient has for years
used Seretide 25/250 mg 2 x 2, theo-
phylline prolonged-release tablet 200
mg in the evening, tiotropium inhala-
tion powder 18 microg 1 x 1 and, as
necessary, salbutamol inhalation 100
microg. On diagnosing asthma in
1995, prick tests showed positive reac-
tions to epithelia from cats and guinea
pigs. The patient had suffered from
atopic dermatitis in childhood.
During her working life the patient
suffered from recurrent bronchitis and
sinusitis, which were often treated with
courses of antibiotics. These usually
included doxicycline and cefalexin, a
few times also azithromycin and once
roxithromycin and a course of cefurox-
ime. In November 1998, after a course
of azithromycin, the patient experi-
enced a short-term facial rash of the
urticaria type. The course was given
during a dark season. But a course of
azithromycin given later on did not
cause a rash.
A 7-day course of telithromycin for
the treatment of bronchitis was started
at the beginning of April. On the sec-
ond day of the course, an itching, ery-
thematous, small papular rash develop-
ed on the light-exposed areas of the
face, neck and upper chest, and the
back of the metacarpal area and the
arms. The itch was intense, even dis-
turbing night-time sleep. The patient
continued using telithromycin for a
period of 5 days. She did not use other
medicines, except for her anti-asthmat-
ic agents.
I met my patient at the beginning
of May and prescribed hydrocortisone-
17-butyrate cream, saline baths and
cetirizine 10 mg 1 x 1 for the
treatment of the rash. A week later the
patient told me that the rash had abat-
ed, there was no itching or redness,
but that some scaling remained.
Certain cosmetic preparations have
caused irritation of the skin, but no
epicutaneus tests have been carried
out. From then on, the patient only
used the basic ointments which usually
did not cause a problem.
My observation of an adverse drug reaction 
Telithromycin and photodermatitis
In English
Leena Savolainen
Dermatologist ADR News
Itä-Suomen Lääkärikeskus
Since 1973, the adverse drug reac-
tion register of NAM in Finland
has received 107 reports of photo-
sensitivity cases. There are no fur-
ther reports associated with the
use of telithromycin; and
azithromycin, one of the
antibiotics of the macrolide group,
has been reported on twice.
Azithromycin is the only
macrolide, the SPC of which
mentions photosensitivity as an
adverse reaction (albeit rare).
The majority of reports on
photosensitivity have concerned
products containing a thiazide
diuretic (14 reports) and tetracy-
clines (13 reports, 7 of which were
on doxicycline). Products contain-
ing ketoprofen have been reported
on 8 times in total (7 of which
concerned the topical
preparation), and piroxicam 6
times (all of them concerning the
oral preparation). Preparations
containing sulpha have been
reported on 6 times (on 4 of
which the trimethoprim combina-
tion product was concerned), and
amiodarone has been reported on
4 times. These reports serve as a
good account of the spectrum of
drugs known to cause photosensi-
tivity.
Annikka Kalliokoski
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From 1998 to 2005 the adverse reac-
tion register of NAM in Finland
received a total of 396 reports of
adverse reactions associated with anti-
depressants. Of these, 268 concerned
women and 126 men. Two reports did
not mention the sex. The Figure repre-
sents the number of reports categorised
into age groups.
The number of reports according
to the category of the active ingredient
are presented in the Table. The report
may involve more than one suspected
drug, and therefore the number of sus-
pected drugs is higher than that of the
reports. Equally, one report may
include one or more symptoms.
A total of 170 reports were received
on the selective serotonin re-uptake
inhibitors (SSRIs), the majority of
which were on sertraline (51), citalo-
pram (44) and paroxetine (27). About
a third of the cases related to various
adverse reactions involving the nervous
system (including headache, dizziness,
tics, seizures, dysaesthesia, sleep distur-
bances, hallucinations, confusion).
Adverse reactions relating to the skin
and the digestive organs (nausea,
abdominal pain, diarrhoea) and oede-
ma were also common. Intentional
overdose was reported on 8 cases. Sero-
tonin syndrome was mentioned in four
reports, two of which were in associa-
tion with an interaction and one with
an overdose. There were also 11
reports about withdrawal symptoms.
Also most of the adverse reactions
associated with the use of mirtazapine,
venlafaxine and reboxetine involved
the nervous system. Adverse reactions
associated with the use of mirtazapine
included seizures (12 reports) and rest-
less legs (6 reports); others were e.g.
dizziness, tremor and headache. Vari-
ous adverse reactions associated with
the skin were also reported, besides
edema; a total of 12 reports were
received on various degrees of leucope-
nia. Oral adverse reactions were report-
ed on 12 times, four of which
concerned stomatitis.
The most common nervous system
adverse reaction associated with
venlafaxine was dizziness. A total of 4
reports were received on the serotonin
syndrome, and 5 on withdrawal symp-
toms. There were also 4 reports on the
prolongation of the QT interval. Of
the 15 reports on mianserin, 8 ment-
ioned agranulocytosis/granulocytope-
nia.
There were a total of 21 adverse
reactions involving 15–19-year-old
adolescents (16 women and 5 men).
The adverse reactions manifested in
this age group were of the same type as
those in older age groups. Intentional
overdosing was reported on three occa-
sions. Reports on complications
involving the newborn totalled 7, all of
them on the SSRI drugs. Some of the
complications involving the newborn
have been recorded in the mother’s
report. Symptoms in the newborn
included, for example, somnolence,
seizures, breathing and eating difficul-
ties.
Adverse reactions due to antidepressants
In English
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Senior Medical Officer
Leena Sommarberg
Researcher
Pharmacovigilance
National Agency for Medicines
Adverse reactions due to 
antidepressants 
from 1998 to 2005
Number 
of reports
Tricyclic antidepressants 
(e.g. amitriptyline) 7
Selective serotonin re-uptake 
inhibitors (SSRIs), total 170
sertraline 51
citalopram 44
paroxetine 27
fluoxetine 22
escitalopram 18
fluvoxamine 8
Others, total 227
mirtazapine 106
venlafaxine 53
reboxetine 20
milnacipran 15
mianserin 15
moclobemide 9
duloxetine 5
trazodone 4
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The use of antidepressants in young women 
has increased 
The consumption of antidepressants
took an upward turn in Finland and
other Western countries at the end of
the 1980s, i.e. after the introduction of
group SSRI drugs with a new mecha-
nism of action. According to the sales
records of medicinal products of NAM
in Finland, the consumption had
increased seven-fold in 2005 compared
with the year 1990. The Social Insur-
ance Institution statistics for refunds
show that 328,000 individuals, or
6.3% of the population, were
reimbursed for these drugs last year.
The proportion of women was 7.8%
and of men 4.6%.
In 2005, a great regional variation
in the use was seen (See map on page
18). The use was most common in
Pohjois-Savo, where the proportion of
the population using these drugs
reached over 7%. The next largest pro-
portions were found in Pohjois-Karjala
and Varsinais-Suomi. The consump-
tion was smallest in the hospital
districts of Länsi-Pohja and Lappi,
where it was about 5%. The highest
figure for consumption in the health-
care centre districts was found at
Hyrynsalmi, 9.2%, while Heinävesi
and Rautavaara also nearly reached the
level of 9%.
Citalopram is the most
commonly used 
The antidepressant most commonly
used in Finland ever since the first
years of the 1990s has been citalo-
pram. The number of people receiving
a refund for it in 2005 was 99,000.
Mirtazapine was the next most
commonly used, with 64,000 people
receiving a refund, and escitalopram
came in third place with 49,000 recipi-
ents of a refund. Among the old anti-
depressants, amitriptyline was the most
frequently used with 19,500 recipients
of a refund, while 11,500 people had
used doxepin. A proportion of the
consumption of amitriptyline may
have been for the treatment of chronic
pain.
Prices reduced through 
generic substitution
The end of patent protection has
introduced several important
antidepressants into the generic substi-
tution sector. This is shown in the
strong decrease in their consumer spe-
cific costs (Fig. 1). Among the drugs
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mostly used, only venlafaxin and esci-
talopram have retained a relatively sta-
ble cost level. Citalopram, paroxetine
and fluoxetin in particular have been
at the centre of tough price competi-
tion, and certraline was targeted by
price competition during 2005. Mir-
tazapine is already also available as a
number of generic products, and its
average cost level has started on a
downward trend. Calculated per con-
sumer, the cost of the most commonly
used antidepressant, citalopram, was
less than a fifth of that of the most
expensive one, venlafaxine.
As a result of the price competit-
ion, the cost of antidepressants in out-
patient care has decreased in the last
couple of years. In 2002, i.e. before the
generic substitution, the total costs of
this drug group amounted to 80 mil-
lion euros, whereas the corresponding
figure last year was 65 million.
The use is most frequent
among the elderly, while 
adolescent use has been
increasing
Last year the frequency of use varied
greatly by age group. The consumption
curves had two peaks, i.e. 50 to 59-
year-old patients used these drugs
more commonly than the next
younger and older age groups. The sec-
ond, and at the same time higher, peak
was found among the over 85-year-
olds. Among the female patients the
frequency of use was 1.7 fold that of
the 70 to 74-year-olds. On another
study, the consumption was found to
become frequent up until the age of
about 90 years.
Special attention has recently been
focused on the use of antidepressants
by children and adolescents, because
this is considered to be associated with
self-destruction. From 1998 to 2005
the proportion of 15 to 19-year-old
women receiving refunds for anti-
depressants has nearly trebled, and in
men in that age group it has doubled
(Fig. 2). Consumption in the groups
younger than this has clearly been
rarer, nor has it become generalised.
The difference between the sexes in the
frequency of use in 15 to 19-year-olds
has been relatively wide for the whole
period reviewed, and men have only
now reached the level at which young
women already were in 1998.
Review
The use of antidepressants has been
under lively discussion for as long as
two decades. Concern has been
expressed about the rapid increase in
their use, while it is also considered
that prevanlence of depression has
increased and a proportion of the
depressed has been left without med-
ical treatment. According to a Health
2000 study in Finland, about 7% of
adults aged 30 years and over suffered
from a severe state of depression. The
proportion of antidepressant users in
the population shown in the statistics
is therefore of the same magnitude as
the prevalence of severe depression.
This, however, does not reveal whether
there are any false positives among the
users, or how many of those in need of
treatment have been left without it.
The number of elderly among the
users in particular is essentially higher
than the prevalence of severe
depression in the group would necessi-
tate.
The use of antidepressants has
increased in recent years relatively
rapidly among the 15 to 19-year-olds,
and among women of the age group in
particular. Reports of self-destruction
associated with the use of antidepres-
sants in this age group have been
received recently to such a degree that
warnings about it have been added in
the patient information leaflets of sev-
eral drugs. Careful monitoring of the
effect of these warnings on the
treatment practices during the current
year is recommended.
In English
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In 2004, 499,658 people with chronic
hypertension, 194,369 with coronary
artery disease and 64,135 with cardiac
insufficiency were entitled to a special
refund of the price of their medication.
Some of these people enjoyed several
entitlements to a refund (1).
The main group of drugs used in
the treatment of hypertension includes
diuretics, beta-blockers, calcium chan-
nel blockers, ACE inhibitors and
angiotensin receptor antagonists,
which all have an approximately equal
hypotensive effect (2). A combination
of two or more drugs is needed in over
half of the patients to achieve the treat-
ment target (3). Beta-blockers were the
most commonly used antihypertensives
(either alone or in combination) in the
study by Rantanen et al. (4). The use
of diuretics in Finland is too low in
relation to the efficacy proven and the
associated benefits (4, 5).
The consumption of antihyperten-
sives has increased in all the Nordic
countries during 1999–2003. Diuretics
were the treatment of choice during
this period in Denmark and Sweden
more often than in the other Nordic
countries. The use of beta-blockers was
becoming more common in all the
Nordic countries, but their consump-
tion (DDD/1,000 inh./day) in Den-
mark was half that in Finland or Swe-
den. In relation to population, the
consumption of combination products
of ACE inhibitors and diuretics was
highest in Finland, and the consump-
tion of combination products of
angiotensin receptor antagonists and
diuretics highest in Norway (6).
The aim of the study was to estab-
lish which antihypertensives were in
use, and how the consumption and
costs of drugs were distributed in Fin-
land with regard to income level, edu-
cational level, age, sex, mother tongue
and employment status in 2004. Drug
therapies were also reviewed from the
viewpoint of the recommended treat-
ment in hypertension and some associ-
ated diseases (2, 3).
The study was carried out as a reg-
ister review based on the data of the
Social Insurance Institution and the
Statistical Finland. The study subjects
were randomly chosen among people
with special refund entitlement from
the Social Insurance Institution for the
drugs they used for chronic hyperten-
sion (205) and/or chronic coronary
heart disease (206) and/or chronic car-
diac insufficiency (201). Their
prescription data were checked and all
drugs classified as antihypertensives
were included in the study irrespective
of which of these three special refund
entitlements the drugs were assigned
to. The study included potassium
(A12B), antihypertensives (C02),
diuretics (C03), beta-blockers (C07),
calcium channel blockers (C08), ACE
inhibitors (C09A/C09B) and
angiotensin receptor antagonists
(C09C/C09D) (7).
Results
The subjects of the study were
335,879 individuals on antihyperten-
sive therapy. The data were collected
from 53% of those with special refund
entitlement for  antihypertensives,
59% of those with special refund enti-
tlement for cardiac insufficiency and
31% for coronary heart disease during
2004.
The use of antihypertensives was
relatively more common in women, in
older people, in those of Finnish
mother tongue, in those with a lower
level of education, and in those living
in eastern Finland and small munici-
palities, rather than in men, in
younger people, in those of Swedish or
other mother tongue, those with a
higher level of education, or those liv-
ing in either southern or south-western
Finland and/or in large municipalities.
The most common antihyperten-
sive therapies consisted of either a
beta-blocker alone and/or a combina-
tion product containing it (19%), an
ACE inhibitor alone and/or a combi-
nation product containing it (8%), a
beta-blocker together with an ACE
inhibitor and/or a combination prod-
uct containing it (7%) and a beta-
blocker together with a calcium chan-
nel blocker and/or a combination
product containing it (7%). The use of
ACE inhibitors in men under  the age
of 65 was slightly more common than
the use of beta-blockers, whereas the
situation in women was the reverse.
The use of calcium channel blockers in
men older than this was relatively
more common, whereas in women the
use of diuretics became more common
with age.
The groups of antihypertensives
most commonly used and number of
users are presented in the Table. The
subjects had an average of 2 antihyper-
tensives in use during the year: 38%
were using one, 33% two and 18%
three antihypertensives.
The Finnish Treatment recommen-
dations for hypertension were fairly
well adhered to in respect of people
suffering from coronary heart disease,
cardiac insufficiency and diabetes. Of
the patients who had asthma in addi-
tion to cardiovascukar disease 23%
used beta-blockers and/or combination
products containing them, whereas the
percentage for all the study patients
was 59%. One and a half percent of
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the asthma patients were using a non-
selective beta-blocker. According to the
treatment recommendation, however,
beta-blockers are usually contraindicat-
ed in asthma patients. In compelling
circumstances (such as coronary heart
disease), either as potent a beta-1-selec-
tive blocker as possible or a blocker
with an additional beta-2-agonist effect
may be used (2).
The cost of antihypertensives per
person Finland in 2004 was on average
EUR 301. The cost of drugs increased
with age up to the age of 55–59 years,
after which it diminished again. In
relation to other socio-economic vari-
ables, there were no significant differ-
ences in the cost of drugs. The annual
costs for individuals using one drug
only were on average EUR 157, for
those using two drugs EUR 313, and
for those using three drugs EUR 430.
The costs for antihypertensive drugs in
diabetics were higher than in others,
an average of EUR 366, owing to the
stricter target level of blood pressure in
diabetics and, consequently, the
increased medication.
Conclusion
The use of antihypertensives
corresponded fairly well with the treat-
ment recommendations. Beta-blockers
and diuretics and/or combinations
containing them remained the most
common antihypertensives. Over a half
of the study subjects used more than
one antihypertensive. Almost one in
every four asthma patients used beta-
blockers, which did not comply with
the Finnish Treatment recommenda-
tions except under compelling circum-
stances (such as if the patient was suf-
fering from a coronary heart disease).
The prevalence of use differed by sex
and age group.
The differences in drug costs
between individuals were relatively
speaking highest among those on one
antihypertensive alone. The least
expensive drugs were the diuretics and
the most expensive ones the angio-
tensin receptor antagonists. When sev-
eral drugs were used, the costs
increased almost linearly with the
number of drugs. The annual costs of
antihypertensives for diabetics were
higher than those for others.
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In English
The antihypertensives most commonly used and number of users
Antihypertensive and/or Number of users 
a combination product 
Beta-blocker 197,000
Diuretic 171,000
ACE inhibitor 120,000
Calcium channel blocker 113,000
Angiotensin receptor antagonist 72,000
